FDA Shares Adaptive Design for Highly Variable Drug Bioequivalence Studies

CDER has developed a new adaptive crossover trial design that can be used in demonstrating the bioequivalence (BE) of generic versions of drugs with high pharmacokinetic (PK) variability.
Source: Drug Industry Daily